Sage Impresses With Second Postpartum Depression Therapy

 
• By John Davis

Positive top-line Phase III data with Sage's second lead positive allosteric modulator at GABA receptors, SAGE-217, in postpartum depression continues to back the US biotech's approach to the devastating condition.  

Depression
Postpartum depression can be devastating for mothers and their families • Source: Shutterstock

More from Clinical Trials

More from R&D